SAGE is a neuroscience-focused company discovering medicines to treat life-threatening, rare CNS disorders. Launched in 2010, SAGE is a publicly traded company led by an experienced team of leaders, CNS experts and investors. Our lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many in an exciting portfolio of potential seizure medicines. We are fearless in our pursuits to deliver these new medicines to patients and their families with one simple goal in mind: to make their lives better.
Our mission is to make life better for patients with central nervous system diseases by discovering, developing and delivering important new medicines to patients in need.